Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol
British Journal of Clinical Pharmacology2015Vol. 80(6), pp. 1399–1410
Citations Over TimeTop 16% of 2015 papers
Herbert Wiesinger, Matthias Berse, Stefan Klein, Simone Gschwend, Joachim Höchel, Frank S. Zollmann, Barbara Schütt
Abstract
A moderate pharmacokinetic drug-drug interaction between DRSP and KTZ was demonstrated in this study. No relevant changes of medical concern were detected in the safety data collected in this study.
Related Papers
- → A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers(2000)59 cited
- → A Comparison of the Cycle Control, Safety, and Efficacy Profile of a 21-Day Regimen of Ethinylestradiol 20??g and Drospirenone 3mg with a 21-Day Regimen of Ethinylestradiol 20??g and Desogestrel??150??g(2006)26 cited
- → Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers(2000)62 cited
- → Drospirenone/Ethinylestradiol: A Review on Efficacy and Noncontraceptive Benefits(2010)15 cited
- → Risk of Thromboembolism in Women Taking Ethinylestradiol/Drospirenone and Other Oral Contraceptives(2008)9 cited